Research
Hormonal
Short-term intensive insulin therapy (SIIT) using continuous subcutaneous insulin infusion or multiple daily injections for 2-3 weeks can induce sustained drug-free remission in newly diagnosed type 2 diabetes patients by restoring beta-cell function and reducing glucotoxicity.
If you were recently diagnosed with high blood sugar, ask your doctor about a short course of intensive insulin therapy (2-3 weeks). This 'reset' can restore your body's ability to manage blood sugar on its own, potentially allowing you to avoid lifelong medication.
GoodSupportsHIGH confidence
SIIT is a validated strategy for T2DM reversal... delivered via continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDIs)... A recent multicenter RCT... 48% maintained their HbA1c below 6.5% after 48 weeks—a result classified as successful diabetes remission... Early SIIT was found to significantly improve b-cell function and insulin sensitivity, laying the foundation for long-term glycemic control without medication for some patients.
Why this rating
Supported by a multicenter RCT (n=412) and other medium-scale RCTs, though long-term durability varies.
Source
Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives
Yang Liu et al. · Frontiers in Endocrinology · 2025
DOI 10.3389/fendo.2025.1687601
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Combination therapies involving GLP-1 receptor agonists (GLP-1RAs) and insulin, or comprehensive metabolic interventions including metformin, significantly increase diabetes remission rates compared to standard care.Good
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates significant potential for achieving prediabetes and type 2 diabetes remission through superior glycemic control and weight loss compared to other GLP-1RAs.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →